McNicoll Lewis & Vlak Downgrades Genomic Health Inc. (GHDX) to Hold
GHDX Hot Sheet
Rating Summary:4 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 11 | New: 36
McNicoll Lewis & Vlak downgraded Genomic Health Inc. (NASDAQ: GHDX) from Buy to Hold, price target cut from $31.50 to $30.00.
For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.
Shares of Genomic Health Inc. closed at $26.57 yesterday, with a 52 week range of $19.00-$29.52.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.
Shares of Genomic Health Inc. closed at $26.57 yesterday, with a 52 week range of $19.00-$29.52.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Nomura Securities Maintains a 'Buy' on Melco Crown Entertainment (MPEL); Raising PT and Estimates
- Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
- Mizuho Securities Downgrades Dell (DELL) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
